Findings

What do systematic reviews say?

118 questions · 128 findings · 7 reviews · Metabolic and Endocrine Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 46 · 35.9%GRADE not reported 2 · 1.6%Very low 53 · 41.4%Low 17 · 13.3%Moderate 10 · 7.8%High 0 · 0%

Adverse event outcomes for dietary combined with physical activity interventions vs usual care

Health-related quality of life (after at least 5 years follow-up) · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 2144 participants
Very low

Adverse event outcomes for dietary combined with physical activity interventions vs usual care

Costs (direct costs of interventions) · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2775 participants
Low

Diet vs physical activity or standard treatment

All‐cause mortality · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 530 participants
Very low

Diet vs physical activity or standard treatment

Development of type 2 diabetes · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 530 participants
Very low

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

All‐cause mortality · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Metformin · people at increased risk for developing type 2 diabetes

2 findings from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 201 participants
Low
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Acarbose · people at increased risk for developing type 2 diabetes

2 findings from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
Very low
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Repaglinide · people at increased risk for developing type 2 diabetes

2 findings from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 103 participants
Low
Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Cardiovascular mortality · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Socioeconomic effects · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention

All‐cause mortality · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention

Incidence of T2DM (N) · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
Low

Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention

Serious adverse events (N) · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 103 participants
Low

Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention

Cardiovascular mortality · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention

Non‐fatal myocardial infarction/stroke · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention

Health‐related quality of life · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs intensive behaviour‐changing intervention

Socioeconomic effects · people at increased risk for developing type 2 diabetes

The review found no eligible studies for this question.

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: pioglitazone monotherapy vs placebo

All‐cause mortality · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
2.38 [0.54, 10.5]
4 studies · 1156 participants
Very low

Summary of findings: pioglitazone monotherapy vs placebo

Incidence of T2DM (N) · people at increased risk for developing type 2 diabetes

Summary of findings: pioglitazone monotherapy may leads to lower incidence of T2DM (N) Diagnostic criteria: 3 studies applied the WHO… compared with placebo (low certainty).

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
RR 0.4 [0.17, 0.95]
6 studies · 1395 participants
Low

Summary of findings: pioglitazone monotherapy vs placebo

Serious adverse events (N) · people at increased risk for developing type 2 diabetes

1 finding from 1 review

Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
3 [0.32, 28.22]
2 studies · 187 participants
Very low